APA (7th ed.) Citation

MA, H., C, G., H, J., RM, C., BL, B., EM, S., . . . AC, W. (2025). EA1211: Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). Future oncology (London, England), 21(26), 3377. https://doi.org/10.1080/14796694.2025.2567840

Chicago Style (17th ed.) Citation

MA, Hennessy, et al. "EA1211: Interim FDG-PET/CT for Predicting Response of HER2-positive Breast Cancer to Neoadjuvant Therapy (DIRECT Trial)." Future Oncology (London, England) 21, no. 26 (2025): 3377. https://doi.org/10.1080/14796694.2025.2567840.

MLA (9th ed.) Citation

MA, Hennessy, et al. "EA1211: Interim FDG-PET/CT for Predicting Response of HER2-positive Breast Cancer to Neoadjuvant Therapy (DIRECT Trial)." Future Oncology (London, England), vol. 21, no. 26, 2025, p. 3377, https://doi.org/10.1080/14796694.2025.2567840.